The Elusive Magic Pill: Finding Effective Therapies for Mitochondrial Disorders

Neurotherapeutics

Volumn 10, Issue 2, 2013, Pages 320-328

  Goldstein, Amy ^a   Wolfe, Lynne A ^b  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

ATP; Mitochondria; mtDNA; nDNA; OXPHOS; Respiratory chain

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ALPHA TOCOPHERYLQUINONE; ALPHA TOCOTRIENOL QUINONE; ANTIOXIDANT; ARGININE; ASCORBIC ACID; BEZAFIBRATE; BRANCHED CHAIN AMINO ACID; CARNITINE; CITRULLINE; CREATINE; DEXPRAMIPEXOLE; GLUTATHIONE; IDEBENONE; MENADIONE; NICOTINAMIDE; NICOTINIC ACID; RESVERATROL; RETINOL; RIBOFLAVIN; SIRTUIN 1; SUCCINIC ACID; THIAMINE; THIOCTIC ACID; UBIQUINONE;

ANTIOXIDANT ACTIVITY; CALORIC RESTRICTION; DIET THERAPY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTRON TRANSPORT; HUMAN; IN VITRO STUDY; INHERITANCE; KETOGENIC DIET; KINESIOTHERAPY; MELAS SYNDROME; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

EID: 84876190301     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-012-0175-0     Document Type: Review

References (44)

1. Koene S, Smeitink J (eds): Mitochondrial Medicine a Clinical Guideline, 1st ed. 2011. Khondrion, Nijimegen.
2. Calvo SE, Mootha VK. The mitochondrial proteome and human disease. Annu Rev Genomics Hum Genet 2010; 11: 25-44.
3. DiMauro S. A history of mitochondrial diseases. J Inherit Metab Dis 2011; 34: 247-248.
4. Elliot H, Samules DC, Eden JA, et al. Pathogenic mitochondrial DNA mutations are common in the general population. Am J Hum Genet 2008; 83: 254-260.
5. Johns DR. Mitochondrial DNA and disease. N Engl J Med 1995; 333: 638-44.
6. Thorburn DR, Chow CW, Kirby DM. Respiratory chain enzyme analysis in muscle and liver. Mitochondrion 2004; 4: 363-375.
7. Pfeffer G, Majamaa K, Turnbull DM, Thorburn D, Chinnery PF. Treatment of mitochondrial disorders. Cochrane Database Syst Rev 2012. doi: 10. 1002/14651858. CD004426. pub3.
8. DiMauro S and Schon EA. Mitochondrial disorders in the nervous system. Annu Rev Neurosci 2008; 31: 91-123.
9. Schiff M, Benit P, Coulibaly A, Loublier S, El-Khoury R, Rustin P. Mitochondrial response to controlled nutrition in health and disease. Nutrition Rev 2011; 69: 65-75.
10. Acin-Perez R, Hoyos B, Zhao F, et al. Control of oxidative phosphorylation by vitamin A illuminates a fundamental role in mitochondrial energy homoeostasis. FASEB J 2010; 24: 627-636.
11. Matsubara K, Kayashima T, Mori Masaharu, Yoshida H, Mizushina Y. Inhibitory effects of vitamin K3 on DNA polymerase and angiogenesis. Int J Mol Med 2008; 22: 381-387.
12. Klopstock T, Yu-Wai-Man P, Dimitriadis K, et al. A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain 2011; 134: 2677-2686.
13. Nasser M, Javaheri H, Fedorowicz Z, Noorani Z. Carnitine supplementation for inborn errors of metabolism. Cochrane Database Syst Rev 2012. doi: 10. 1002/14651858. CD006659. pub3.
14. Packer L, Cadenas E. Lipoic acid: energy metabolism and redox regulation of transcription and cell signaling. J Clin Biochem Nutr 2011 48: 26-32.
15. Rodriguez MC, MacDonald JR, Mahoney DJ, Parise G, Beal MF, Tarnopolsky MA. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007; 35: 235-242.
16. DeStefano N, Matthews PM, Ford B, Genge A, Karpati G, Arnold DL. Short-term dichloracetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders. Neurology 1995; 45: 1193-1198.
17. Duncan GE, Perkins LA, Theriaque DW, Neiberger RE, Stacpoole PW. Dichloroacetate therapy attenuates the blood lactate response to submaximal exercise in patients with defects in mitochondrial energy metabolism. J Clin Endocrinol Metab 2004 8: 1733-1738.
18. Vissing J, Gansted U, Quistorff B. Exercise intolerance in mitochondrial myopathy is not related to lactic acidosis. Ann Neurol 2001; 49: 672-676.
19. Stacpoole PW, Kerr DS, Barnes C, Bunch ST, Carney PR, Fennell EM, et al. Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 2006; 117: 1519-1531.
20. Bastin J, Lopes-Costa A, Djouadi F. Exposure to resveratrol triggers pharmacological correction of fatty acid utilization in human fatty acid oxidation-deficient fibroblasts. Hum Mol Genet 2011; 20: 2048-2057.
21. Koga Y, Akita N, Junko N et al. Endothelial dysfunction in MELAS improved by L-arginine supplementation. Neurology 2006; 66: 1766-1769.
22. Koga Y, Povalko N, Nishioka J, Katayama K, Kakimoto N, Matsuishi T. MELAS and L-arginine therapy: pathophysiology of stroke-like episodes. Ann NY Acad Sci 2010; 1201: 104-110.
23. El-Hattab AW, Emrick LT, Craigen WJ, Scaglia F. Citrulline and arginine utility in treating nitric oxide deficiency in mitochondrial disorders. Mol Genet Metab 2012; 107: 247-252.
24. Kang HC, Lee YM, Kim HD, Lee JS, Slama A. Safe and effective use of the ketogenic diet in children with epilepsy and mitochondrial respiratory chain complex defects. Epilepsia 2007; 48: 82-88.
25. Kossoff EH, Zupec-Kania BA, Rho JM, Ketogenic diets: an update for child neurologists. J Child Neurol 2009; 24: 979-988.
26. Lin SJ, Ford E, Haigis M, Liszt G, Guarente L. Calorie restriction extends yeast life span by lowering the level of NADH. Genes Dev 2004; 18: 12-16.
27. Yang H, Yang T, Baur JA, et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 2007; 130: 1095-1107.
28. Imai S, Guarente L. Ten years of NAD-dependent SIR2 family deacetylases: implications for metabolic diseases. Trends Pharmacol Sci 2010; 31: 212-220.
29. Safdar A, Little JP, Stokl AJ, Hettinga BP, Akhtar M, Tarnopolsky MA. Exercise increases mitochondrial PGC-1alpha content and promotes nuclear-mitochondrial cross-talk to coordinate mitochondrial biogenesis. J Biol Chem 2011; 286: 10605-10617.
30. Murphy JL, Blakely EL, Schaefer AM, He L, Wyrick P, Haller RG, et al. Resistance training in patients with single, large-scale deletions of mitochondrial DNA. Mitochondrial Research Group, Newcastle University, Framlington Place, Newcastle upon Tyne, UK. Brain 2008; 131: 2832-2840.
31. Taivassalo T, Gardner JL, Taylor RW, Schaefer AM, Newman J, Barron MJ, et al. Endurance training and detraining in mitochondrial myopathies due to single large-scale mtDNA deletions. Brain 2006; 129: 3391-3401.
32. Safdar A, Bourgeois JM, Ogborn DI, Little JP, Hettinga BP, Akhtar M, et al. Endurance exercise rescues progeroid aging and induces systemic mitochondrial rejuvenation in mtDNA mutator mice. Proc Natl Acad Sci U S A 2011; 108: 4135-4140.
33. Jeppesen TD, Schwartz M, Olsen DB, et al. Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. Brain 2006; 129: 3402-3412.
34. Taivassalo T, Haller RG. Exercise and training in mitochondrial myopathies. Med Sci Sports Exerc 2005; 37: 2094-2101.
35. Hou X, Xu S, Maitland-Toolan KA, Sato K, Jiang B, Ido Y, et al. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-Activated protein kinase. J Biol Chem 2008; 83: 20015-20026.
36. Yatsuga S, Suomalainen A. Effect of bezafibrate treatment on late-onset mitochondrial myopathy in mice. Hum Mol Genet 2012; 21: 526-535.
37. Wang Y, Mohsen AW, Mihalik SJ, Goetzman ES, Vockley J. Evidence for physical association of mitochondrial fatty acid oxidation and oxidative phosphorylation complexes. J Biol Chem 2010; 285: 29834-29841.
38. Enns GM, Bennett MJ, Hoppel CL, Goodman SI, Weisiger K, Ohnstad C, et al. Mitochondrial respiratory chain complex I deficiency with clinical and biochemical features of long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. J Pediatr 2000; 136: 1-4.
39. Haack TB, Danhauser K, Haberberger B, Hoser J, Strecker V, Boehm D, et al. Exome sequencing identifies ACAD9 mutations as a cause of complex I deficiency. Nat Genet 2010; 42: 1131-1134.
40. Calvo SE, Compton AG, Hershman SG, Lim SC, Lieber DS, Tucker EJ, et al. Molecular diagnosis of infantile mitochondrial disease with targeted next-generation sequencing. Sci Transl Med 2012; 25: 118: 118ra10.
41. Enns GM, Kinsman SL, Perlman SL, Spicer KM, Abdenur JE, Cohen BH, et al. Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol Genet Metab 2012; 105(1): 91-102.
42. Sadun AA, Chicani CF, Ross-Cisneros FN, Barboni P, Thoolen M, Shrader WD, et al. Effect of EPI-743 on the clinical course of the mitochondrial disease leber hereditary optic neuropathy. Arch Neurol 2012; 69: 331-338.
43. Martinelli D, Catteruccia M, Piemonte F, Pastore A, Tozzi G, Dionisi-Vici C, et al. EPI-743 reverses the progression of the pediatric mitochondrial disease-denetically defined Leigh syndrome. Mol Genet Metab 2012; 107: 383-388.
44. Alavian KN, Dworetzky SI, Bonanni L, Zhanga P, Sacchetti S, Mariggio MA, et al. Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency. Brain Res 2012; 1446: 1-11.